VEDAPROFEN

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H22O2
Molecular Weight	282.3768
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC=C(C2CCCCC2)C3=CC=CC=C13

InChI

InChIKey=VZUGVMQFWFVFBX-UHFFFAOYSA-N

InChI=1S/C19H22O2/c1-13(19(20)21)15-11-12-16(14-7-3-2-4-8-14)18-10-6-5-9-17(15)18/h5-6,9-14H,2-4,7-8H2,1H3,(H,20,21)

HIDE SMILES / InChI

Description
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000032/WC500067567.pdf

Vedaprofen is a PGE2 synthase inhibitor approved in Europe for the treatment of pain in horses and dogs.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 2 51 Target ID: O19183 Gene ID: 791253.0 Gene Symbol: PTGS2 Target Organism: Equus caballus (Horse) Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000032/WC500067567.pdf	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/000032/WC500067563.pdf	Primary		Approved 8583	QUADRISOL Approved Use Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma). Launch Date 1997

PubMed

Title	Date	PubMed
Treatment of persistent mating-induced endometritis in mares with the non-steroid anti-inflammatory drug vedaprofen.	2010-12	20074320
Practical experience with the treatment of recipient mares with a non-steroidal anti-inflammatory drug in an equine embryo transfer programme.	2010-12	19515030
Analgesic efficacy of perioperative use of vedaprofen, tramadol or their combination in cats undergoing ovariohysterectomy.	2009-06	19233698
Perioperative administration of vedaprofen, tramadol or their combination does not interfere with platelet aggregation, bleeding time and biochemical variables in cats.	2009-06	19168382
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.	2008-02	17408711
Vedaprofen therapy in cats with upper respiratory tract infection or following ovariohysterectomy.	2007-02	17286658
Influence of vedaprofen (Quadrisol) on quality and freezability of stallion semen.	2005-11	15955550
The pharmacokinetics of vedaprofen and its enantiomers in dogs after single and multiple dosing.	2005-06	15953205
Comparison of vedaprofen and meloxicam in dogs with musculoskeletal pain and inflammation.	2002-05	12038853

Sample Use Guides

In Vivo Use Guide

Twice daily administration. An initial dose of 2 mg/kg (2.0 ml/100 kg) is followed by a maintenance dose of 1 mg/kg (1.0 ml/100 kg) given every 12 hours. Treatment can be continued for a maximum of 14 consecutive days.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

VEDAPROFEN FOR VETERINARY USE

Preferred Name

English

VEDAPROFEN

Official Name

English

CERM10202

Code

English

1-NAPHTHALENEACETIC ACID, 4-CYCLOHEXYL-.ALPHA.-METHYL-, (±)-

Common Name

English

VEDAPROFEN [MI]

Common Name

English

CERM-10202

Code

English

VEDAPROFEN [JAN]

Common Name

English

1-NAPHTHALENEACETIC ACID, 4-CYCLOHEXYL-.ALPHA.-METHYL-

Common Name

English

VEDAPROFEN [EMA EPAR VETERINARY]

Common Name

English

vedaprofen [INN]

Common Name

English

VEDAPROFEN [USAN]

Common Name

English

VEDAPROFEN FOR VETERINARY USE [EP MONOGRAPH]

Common Name

English

PM-150

Code

English

QUADRISOL

Brand Name

English

PM150

Code

English

VEDAPROFEN [MART.]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM01AE90